Overview
Syngulon develops original genetic technologies using bacteriocins to improve microbial fermentation. The company operates as a 'Startup in the Labs,' working directly in academic partner laboratories across Belgium, Brazil, France, Germany, The Netherlands, and the UK. Bacteriocins are ribosomally-produced, genetically encoded antimicrobial peptides that can be modified using synthetic biology.
Key people
In the news
- 𝗠𝗼𝗻𝘁𝗵𝗹𝘆 𝗕𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 on Syngulon’s website! We are excited to share our monthly feature highlighting recent advances in bacteriocin science, curating and distilling global publications to make breakthroughs in this fast-moving field more accessible. 🧠 𝙎𝙚𝙥𝙩𝙚𝙢𝙗𝙚𝙧 𝙃𝙞𝙜𝙝𝙡𝙞𝙜𝙝𝙩𝙨: 1. An editorial explores how microbial interactions, including bacteriocin-mediated competition, can guide new strategies against antimicrobial resistance. 2. TattleTail
- Syngulon will be attending AHNTI 2026 in Boston, MA (USA) on,October 26–28. We look forward to connecting with leaders across the animal health, nutrition and technology ecosystem and exploring new opportunities for collaboration and technology licensing. Syngulon develops and licenses bacteriocin-based technologies with applications in animal health, including: * 𝗔𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰-𝗳𝗿𝗲𝗲 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗿𝗲𝗰𝗼𝗺𝗯𝗶𝗻𝗮𝗻𝘁 𝗘. 𝗰𝗼𝗹𝗶 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻, enabling plasmid maintenance without
- Delighted to welcome Julien Damoczi, PhD to Syngulon as 𝗥&𝗗 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿! 𝗝𝘂𝗹𝗶𝗲𝗻 has already worked with us on several research projects during his PhD at UCLouvain. We know the depth of his bacteriocin expertise and the curiosity he brings to a collaboration. His new role builds on that connection between academic research and industrial application. We are looking forward to working with him as we advance Syngulon’s bacteriocin-based technologies. Welcome to the team, 𝗝𝘂𝗹𝗶𝗲𝗻! #SyntheticBiology
- A milestone worth celebrating: Syngulon has reached 2 500 followers on LinkedIn! Thank you to everyone following our work and developments in 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰-𝗳𝗿𝗲𝗲 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻, bacteriocins for 𝗰𝗼𝗻𝘁𝗮𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗰𝗼𝗻𝘁𝗿𝗼𝗹, and 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀. We truly appreciate your interest, interactions and support — and look forward to sharing the next developments with you. Thank you for being part of the Syngulon community! #SyntheticBiology #AntibioticFree #AMR #bacteriocins
- Syngulon at the 2026 AFCC Biobased Economy Conference We are pleased to announce that Guy Hélin, CEO, will speak at the 2026 AFCC Biobased Economy Conference on November 2 in Washington, D.C. (USA). His presentation: “𝗣𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗶𝗻𝗴 𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗮𝗹 𝗰𝗼𝗻𝘁𝗿𝗼𝗹: 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻𝘀 𝗳𝗼𝗿 𝗿𝗼𝗯𝘂𝘀𝘁, 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰-𝗳𝗿𝗲𝗲 𝗯𝗶𝗼𝗯𝗮𝘀𝗲𝗱 𝗯𝗶𝗼𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴” Industrial fermentation faces two persistent challenges: maintaining stable production systems and controlling microbial
- 𝗕𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 | 𝗝𝘂𝗹𝘆-𝗔𝘂𝗴𝘂𝘀𝘁 𝟮𝟬𝟮𝟲 Bacteriocin research continues to reveal both new antimicrobial molecules and new insights into the biological roles these peptides can play in microbial ecosystems. In our latest Scientific Highlights, we selected two recent studies: 🔬 𝗣𝘂𝗺𝗶𝗰𝘆𝗰𝗹𝗶𝗻 𝗔 𝗲𝘅𝗽𝗮𝗻𝗱𝘀 𝘁𝗵𝗲 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗳𝗮𝗺𝗶𝗹𝘆 𝗼𝗳 𝗵𝗶𝗴𝗵𝗹𝘆 𝘀𝘁𝗮𝗯𝗹𝗲 𝗰𝗶𝗿𝗰𝘂𝗹𝗮𝗿 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻𝘀 𝘄𝗶𝘁𝗵 𝘀𝘁𝗿𝗼𝗻𝗴 𝗮𝗻𝘁𝗶-𝗟𝗶𝘀𝘁𝗲𝗿𝗶𝗮
- 𝗡𝗲𝘄 𝗽𝗮𝘁𝗲𝗻𝘁 𝗴𝗿𝗮𝗻𝘁𝗲𝗱 𝗶𝗻 𝗜𝗻𝗱𝗶𝗮 𝗳𝘂𝗿𝘁𝗵𝗲𝗿 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝗶𝗻𝗴 𝗦𝘆𝗻𝗴𝘂𝗹𝗼𝗻’𝘀 𝗴𝗹𝗼𝗯𝗮𝗹 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻 𝗜𝗣 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 We are pleased to announce that the 𝗜𝗻𝗱𝗶𝗮𝗻 𝗣𝗮𝘁𝗲𝗻𝘁 𝗢𝗳𝗳𝗶𝗰𝗲 𝗵𝗮𝘀 𝗴𝗿𝗮𝗻𝘁𝗲𝗱 Syngulon 𝗜𝗻𝗱𝗶𝗮𝗻 𝗣𝗮𝘁𝗲𝗻𝘁 𝗡𝗼. 𝟱𝟵𝟵𝟮𝟵𝟯, entitled: “𝗠𝗲𝘁𝗵𝗼𝗱𝘀 𝗮𝗻𝗱 𝗖𝗼𝗺𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗠𝗮𝗸𝗶𝗻𝗴 𝗕𝗮𝗰𝘁𝗲𝗿𝗶𝗼𝗰𝗶𝗻𝘀 𝗮𝗻𝗱 𝗔𝗻𝘁𝗶𝗺𝗶𝗰𝗿𝗼𝗯𝗶𝗮𝗹 𝗣𝗲𝗽𝘁𝗶𝗱𝗲𝘀.” This new grant further expands the
- Syngulon at BioLogical Control Systems 2026 in Oxford We are pleased to announce that Alex Quintero Yanes, CTO of Syngulon will attend BioLogical Control Systems 2026, taking place at the University of Oxford on 14–15 September 2026. The conference will bring together researchers and industry partners working at the intersection of biology, control engineering and synthetic biology, with discussions spanning gene circuit design, biological process optimisation and the development of more predictable and robust biological
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.